Study of Relatlimab in Combination With Nivolumab in Chinese Participants (RELATIVITY-111)
A Phase 1 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) in Chinese Participants With Advanced Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: BMS Study Connect Contact Center www.BMSStudyConnect.com
- Phone Number: 855-907-3286
- Email: Clinical.Trials@bms.com
Study Contact Backup
- Name: First line of email MUST contain NCT # and Site #.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 201315
- Fudan University Shanghai Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must have histologic or cytological confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable) except for participants with primary central nervous system (CNS) tumors.
- Participants must have received, and then progressed or been intolerant to at least 1 standard treatment regimen in the advanced or metastatic setting (immune check inhibitor-experienced or non-experienced population may be included), if such a therapy exists. Participants who refuse or are ineligible for standard therapy will be allowed to enroll provided their refusal/ineligibility is documented in medical records.
- Eastern Cooperative Oncology Group (ECOG) 0 to 1.
Exclusion Criteria:
- Participants with history of severe and/or life-threatening toxicity related to prior immune therapy (eg, anti-cytotoxic T-lymphocyte-associated protein 4 [anti-CTLA-4] or anti-programmed cell death protein 1 [anti-PD-1]/programmed death-ligand 1 [PD-L1] treatment or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways) except those that are unlikely to re-occur with standard countermeasures (eg, hormone replacement after endocrinopathy).
- Participants with an active, known, or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
- Prior treatment with LAG-3 targeted agents.
Other protocol-defined inclusion/exclusion criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Cohort 1: Relatlimab Dose 1 + Nivolumab
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
|
Experimental: Cohort 2: Relatlimab Dose 2 + Nivolumab
|
Specified dose on specified days
Other Names:
Specified dose on specified days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants with Adverse Events (AEs)
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Number of Participants with Immune-mediated Adverse Events (IMAEs)
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Number of Participants with Serious Adverse Events (SAEs)
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Number of Deaths
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Number of Participants with AEs Leading to Discontinuation
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Number of Participants with Dose-Limiting Toxicities (DLTs)
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Number of Participants with Clinical Laboratory Abnormalities
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Maximum Observed Plasma Concentration (Cmax) of Relatlimab
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Time of Maximum Observed Plasma Concentration (Tmax) of Relatlimab
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Trough-observed serum concentration (Ctrough) of Relatlimab
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Disease Control Rate (DCR) per RECIST v1.1 by Investigator
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Duration of Response (DOR) per RECIST v1.1 by Investigator
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Best Overall Response (BOR) per RECIST v1.1 by Investigator
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Ctrough of Nivolumab
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Observed Serum Concentration at End of Infusion (Ceoi) of Nivolumab
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Percentage of Participants Positive for Anti-drug Antibodies (ADAs) to Relatlimab
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
|
Percentage of Participants Positive for ADAs to Nivolumab
Time Frame: Up to 123 Weeks
|
Up to 123 Weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CA224-111
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.